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Comparison of Calcein Plasma Concentration in Each Ppotato Starch Solution 
Administered in Close and Open Systems in Rats. 
O : Closed system, O: Open system. The data represent the mean :!: S.E. (n = 3 - 6). 
























































































TABLE 1. Pharmacokinetic Parameters of Calcein after i.v. and i.n. Administration of Different Calcein Solutions 








(ng ' min/mL) 
Fc Fo Fr apparent 
(alc') (%,) ((~/o) viscosity 
(mPa ' s) 
i.v. 







137.7 :~: 19.0 
66.6 ~: 8.8 
 2.68 x 104 :~: O.OI x 104 
120 
120 
3.28 x 104d:0.52 x 104 
1.25 x 104 :!: O.15 x 104 
61.2 -
~ 23.4 38.2 
l .O 
b) Potato starch 
close system 
1.0a/(, potato starch 
2.5c/o potato starch 
5.0(~/o potato starch 
7.50/0 potato starch 
open system 
l.Oa/o potato starch 
2.5(~/o potato starch 
5.0c/(? potato starch 









96.5 ~: 10.0 
89.7 :~: 10. 1 
79.1 ~ 2.0 
19.3 i 1.3 
67.5 :~ 13.0 
65.2 :!: 10.0 
48.9 ~~ 9.8 









2.85 x 104 :!: O.22 x 104 
2.32 x 104i: 0.22 x 104 
l.79 x 104 :~: 0.09 x 104 * 
O.53 x 104:t;O.OI x 104 * 
1.83 x 104~:0.36 x 104 
1.56 x 104:~0.25 x 104 
1.34 x 104:~:0.13 x 104 

















c) Tapioca starch 
close system 
O.5% tapioca starch 
1.00/0 tapioca starch 
2.5r7c tapioca starch 
open system 
O.5f7(; tapioca starch 
1.0(7c tapioca starch 







94.9 ~ 9.60 
60.7 :!: 6.70 
28.6 d~ 2. I O 
62.7 ~: 12.0 
51.2 :t 11.0 







2.52 x 104 :~ 0.29 x 104 
l.83 x 104:!: 0.08 x 104 * 
O.79 x 104:t 0.05 x 104 * 
1.65 x 104:!: O.31 x 104 
1.25 x 104:k 0.16 x 104 
O.67 x 104:!: 0.05 x 104 * 
47.  - - 2.5 34.0  - 7.2 14.7  - over 100 
- 30.7 65.3 
~~* 23.3 68.4 
- 12.5 85.4 
The data represent the mean :~: S.E. (n = 3 - 6). 
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Release Profile of Calcein from Starch Solution. 
(a). O: control, []: 1.0a/o potato starch, A: 2.5% potato starch, <>: or.O(;!7a potato starch, 
V: 7.5%, potato starch. (b) O: control, E: 0.5% tapioca starch, A: l.Oa/o tapioca 
starch, c: 2.5~/'(~ tapioca starch. The data represent the mean :~: S.E. (n, = 3'). 
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